Avalo Therapeutics Inc. logo

Avalo Therapeutics Inc.

AVTX | NASDAQ
Chart Builder DCF Calculator
$16.17
-$0.40 (-2.41%)
At close: Sep 21, 2026, 4:00 PM ET
$16.17
$0 (0.00%)
After-hours: Sep 21, 2026, 7:30 PM ET

Market Data

Market Cap
$849.99M
Enterprise Value
$449.71M
Beta
0.79
Average Volume
1.62M
Shares Outstanding (Diluted)
43.6M
Shares Change YoY
302.61%
Institutional Ownership
N/A
Exchange
NASDAQ
ISIN
US05338F3064

Price Performance

Price Change 1M
-17.8%
Price Change 3M
-9.3%
Price Change 6M
15.9%
Price Change YTD
-5.0%
Price Change 1Y
38.2%
Price Change 3Y
-43.4%
Price Change 5Y
-99.8%
1M CAGR (ann.)
-11.7%
1Y CAGR (ann.)
36.1%
5Y CAGR (ann.)
-70.9%
All-Time CAGR
-47.5%

Valuation

PE Ratio
-3.41
Forward PE
N/A
PEG Ratio
0.02
Forward PEG
-0.86
PS Ratio
14,406.54
Forward PS
850.00
PB Ratio
1.89
P/FCF Ratio
-12.81
P/Adj. FCF Ratio
-10.25
P/OCF Ratio
-10.64
EV/Sales
7,622.20
EV/EBIT
-4.49
EV/EBITDA
-4.50
EV/FCF
-6.77
Earnings Yield
-29.3%
FCF Yield
-7.8%
Adj. FCF Yield
-9.8%

Financial Health

Net Cash
$400.28M
Total Debt
$0
Cash & Short-Term Investments
$400.28M
Total Assets
$490.78M
Current Ratio
19.31
Quick Ratio
19.31
Debt / Equity Ratio
0.00
Debt / EBITDA
-0.00
Debt / FCF
-0.00
OCF / Debt
N/A
Interest Coverage
0.00
Altman Z-Score
10.94
Piotroski F-Score
3

Margins & Profitability

Gross Profit Margin
-16861.0%
Operating Profit Margin
-154844.1%
EBITDA Margin
-169552.5%
Net Profit Margin
-170055.9%
FCF Margin
-112505.1%
Adj. FCF Margin
-140542.4%
SBC / Revenue
28037.3%
SBC Impact (per share)
-24.9%

Returns

Return on Assets
-20.4%
Return on Equity
-58.0%
Return on Invested Capital
-19.4%
Return on Capital Employed
-19.4%
Return on Tangible Assets
-20.9%

Historical Growth (CAGR)

Revenue CAGR 3Y
-84.8%
Revenue CAGR 5Y
-60.9%
Revenue CAGR 10Y
-21.3%
EPS CAGR 3Y
150.0%
EPS CAGR 5Y
83.7%
EPS CAGR 10Y
14.4%
FCF CAGR 3Y
-35.1%
FCF CAGR 5Y
-8.1%
FCF CAGR 10Y
-19.1%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
10
EPS Growth Next 3Y
7.4%
Revenue Growth Next 3Y
431.1%
Earnings Date
Nov 4, 2026
EPS Estimate (next Q)
-$0.63
EPS Growth Est (next Q)
-71.2%
Revenue Est (next Q)
N/A
Revenue Growth Est (next Q)
N/A

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$45.13
Price Target Upside
179.1%

Cash Flow

Operating Cash Flow
$-66.38M
Free Cash Flow
$-66.38M
Adj. Free Cash Flow
$-82.92M
FCF Per Share
-$1.52
OCF Per Share
-$1.52
OCF/S Ratio
-112505.1%

Income Statement

Revenue
$59K
Gross Profit
$-9.95M
Operating Income
$-91.36M
EBITDA
$-100.04M
Net Income
$-100.33M
EPS (Diluted)
-$4.74
Revenue / Employee
$1.79K
Profit / Employee
$-3.04M
Employees
33

© 2026 bestshares.com. All rights reserved.